|
US5023321A
(en)
|
1982-12-13 |
1991-06-11 |
Howard Florey Institute Of Experimental Physiology & Medicine |
Molecular cloning and characterization of a further gene sequence coding for human relaxin
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4682195A
(en)
|
1985-09-30 |
1987-07-21 |
General Electric Company |
Insulated gate device with configured emitter contact pad
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4835251A
(en)
|
1986-06-23 |
1989-05-30 |
Genetech, Inc. |
Method of chain combination
|
|
EP0266032A1
(en)
|
1986-08-29 |
1988-05-04 |
Beecham Group Plc |
Modified fibrinolytic enzyme
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5302523A
(en)
|
1989-06-21 |
1994-04-12 |
Zeneca Limited |
Transformation of plant cells
|
|
US5550318A
(en)
|
1990-04-17 |
1996-08-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US7705215B1
(en)
|
1990-04-17 |
2010-04-27 |
Dekalb Genetics Corporation |
Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
|
|
US5322783A
(en)
|
1989-10-17 |
1994-06-21 |
Pioneer Hi-Bred International, Inc. |
Soybean transformation by microparticle bombardment
|
|
US5484956A
(en)
|
1990-01-22 |
1996-01-16 |
Dekalb Genetics Corporation |
Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
|
|
US5466468A
(en)
|
1990-04-03 |
1995-11-14 |
Ciba-Geigy Corporation |
Parenterally administrable liposome formulation comprising synthetic lipids
|
|
US5384253A
(en)
|
1990-12-28 |
1995-01-24 |
Dekalb Genetics Corporation |
Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
US5610042A
(en)
|
1991-10-07 |
1997-03-11 |
Ciba-Geigy Corporation |
Methods for stable transformation of wheat
|
|
DE4204650C1
(https=)
|
1992-02-15 |
1993-07-08 |
Hoffmeister, Helmut, Dr., 4400 Muenster, De |
|
|
DE69334225D1
(de)
|
1992-07-07 |
2008-07-31 |
Japan Tobacco Inc |
Verfahren zur transformation einer monokotyledon pflanze
|
|
US5702932A
(en)
|
1992-07-20 |
1997-12-30 |
University Of Florida |
Microinjection methods to transform arthropods with exogenous DNA
|
|
WO1994002620A2
(en)
|
1992-07-27 |
1994-02-03 |
Pioneer Hi-Bred International, Inc. |
An improved method of agrobacterium-mediated transformation of cultured soybean cells
|
|
DE4228457A1
(de)
|
1992-08-27 |
1994-04-28 |
Beiersdorf Ag |
Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
|
|
GB9222888D0
(en)
|
1992-10-30 |
1992-12-16 |
British Tech Group |
Tomography
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
AU7326594A
(en)
|
1993-07-09 |
1995-02-06 |
Synergen, Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
ATE397066T1
(de)
|
1993-10-27 |
2008-06-15 |
Univ Columbia |
Methode zur bildung einer subtrahierten cdna bank und ihre verwendung
|
|
US5656610A
(en)
|
1994-06-21 |
1997-08-12 |
University Of Southern California |
Producing a protein in a mammal by injection of a DNA-sequence into the tongue
|
|
FR2722208B1
(fr)
|
1994-07-05 |
1996-10-04 |
Inst Nat Sante Rech Med |
Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5736524A
(en)
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
|
IE80468B1
(en)
|
1995-04-04 |
1998-07-29 |
Elan Corp Plc |
Controlled release biodegradable nanoparticles containing insulin
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US5811395A
(en)
|
1995-06-07 |
1998-09-22 |
Medical University Of South Carolina |
Relaxin analogs and derivatives methods and uses thereof
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
US5705629A
(en)
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
|
US5780448A
(en)
|
1995-11-07 |
1998-07-14 |
Ottawa Civic Hospital Loeb Research |
DNA-based vaccination of fish
|
|
US5928906A
(en)
|
1996-05-09 |
1999-07-27 |
Sequenom, Inc. |
Process for direct sequencing during template amplification
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US5945100A
(en)
|
1996-07-31 |
1999-08-31 |
Fbp Corporation |
Tumor delivery vehicles
|
|
US5710137A
(en)
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
|
US6413544B1
(en)
|
1996-08-19 |
2002-07-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
US5981274A
(en)
|
1996-09-18 |
1999-11-09 |
Tyrrell; D. Lorne J. |
Recombinant hepatitis virus vectors
|
|
US5846225A
(en)
|
1997-02-19 |
1998-12-08 |
Cornell Research Foundation, Inc. |
Gene transfer therapy delivery device and method
|
|
US5736167A
(en)
|
1997-02-27 |
1998-04-07 |
Chang; Hui Hwa |
Mold device for making safety shoe
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US5994624A
(en)
|
1997-10-20 |
1999-11-30 |
Cotton Incorporated |
In planta method for the production of transgenic plants
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
US7589069B1
(en)
|
1999-07-12 |
2009-09-15 |
Saint Louis University |
Replication-competent anti-cancer vectors
|
|
DE60038508T2
(de)
|
1999-07-15 |
2009-04-30 |
Introgen Therapeutics Inc., Austin |
Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
DE60115600T2
(de)
|
2000-01-21 |
2006-07-20 |
Biovex Ltd. |
Virusstämme für die onkolytische behandlung von krebs
|
|
CA2511625A1
(en)
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
KR100523028B1
(ko)
|
2003-02-27 |
2005-10-20 |
윤채옥 |
개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터
|
|
ES2393485T3
(es)
|
2003-07-02 |
2012-12-21 |
Innate Pharma |
Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
|
|
US7803376B2
(en)
|
2003-07-24 |
2010-09-28 |
Innate Pharma S.A. |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
|
US20070281041A1
(en)
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
|
EP2287195B1
(en)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
|
|
EP3072522B1
(en)
|
2005-01-06 |
2019-04-24 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
JP2008528508A
(ja)
*
|
2005-01-21 |
2008-07-31 |
イントロジェン・セラピューティクス，インコーポレイテッド |
標的細胞の治療および予防核酸への持続性の曝露を可能とする局所投与
|
|
KR100747646B1
(ko)
|
2005-02-25 |
2007-08-08 |
연세대학교 산학협력단 |
데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
|
|
US20060257361A1
(en)
|
2005-04-12 |
2006-11-16 |
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services |
Novel form of interleukin-15, Fc-IL-15, and methods of use
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
AU2006301163B2
(en)
|
2005-10-14 |
2012-02-23 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
|
US20100189723A1
(en)
|
2007-01-11 |
2010-07-29 |
Peter Andreas Nicolai Reumert Wagtmann |
Anti-kir antibodies, formulations, and uses thereof
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
NZ582330A
(en)
|
2007-06-27 |
2012-05-25 |
Marinepolymer Tech Inc |
COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
MX2010008168A
(es)
|
2008-01-25 |
2011-02-24 |
P53 Inc |
Biomarcadores p53.
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
CN101658670A
(zh)
|
2008-08-25 |
2010-03-03 |
中国疾病预防控制中心性病艾滋病预防控制中心 |
基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
KR102020018B1
(ko)
|
2009-03-02 |
2019-09-09 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
|
|
GR1006941B
(el)
|
2009-06-01 |
2010-08-27 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Πεπτιδικη συνθεση (peptide synthesis)
|
|
CN102762593B
(zh)
|
2009-07-31 |
2015-05-20 |
梅达雷克斯有限责任公司 |
抗btla的完全人抗体
|
|
WO2011026122A2
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
WO2012009703A2
(en)
|
2010-07-16 |
2012-01-19 |
Epeius Biotechnologies Corporation |
Targeted nanoparticles for cancer and other disorders
|
|
UA113280C2
(xx)
|
2010-11-11 |
2017-01-10 |
|
АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
|
|
CN106963947A
(zh)
|
2010-11-22 |
2017-07-21 |
伊纳特医药股份有限公司 |
Nk细胞调节治疗和用于治疗血液恶性疾病的方法
|
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
|
EP2522726A1
(en)
*
|
2011-05-12 |
2012-11-14 |
Fundació Privada Centre de Regulació Genòmica (CRG) |
Zinc finger nucleases for p53 editing
|
|
SG10201603962TA
(en)
|
2011-05-25 |
2016-07-28 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory disorders
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
|
DK2806883T3
(da)
|
2012-01-25 |
2019-07-22 |
Dnatrix Inc |
Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
|
|
US20150072988A1
(en)
*
|
2012-03-30 |
2015-03-12 |
The Johns Hopkins University |
Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
JP6457940B2
(ja)
|
2012-08-30 |
2019-01-23 |
アムジエン・インコーポレーテツド |
単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
|
|
US20150250837A1
(en)
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
AU2013333938A1
(en)
|
2012-10-16 |
2015-04-09 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
|
CN103110939A
(zh)
|
2012-10-23 |
2013-05-22 |
郑州大学 |
诱导肿瘤特异性免疫的疫苗及其应用
|
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
|
WO2014138314A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
EP2968345B1
(en)
|
2013-03-13 |
2017-12-13 |
The Regents of The University of Michigan |
Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases
|
|
US9407284B2
(en)
|
2013-03-15 |
2016-08-02 |
John W. Ogilvie |
Improvements for Base64 encoding and decoding
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CA2917858A1
(en)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
DK3036329T3
(da)
|
2013-08-22 |
2021-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Immunonkolytiske terapier
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
KR20160093012A
(ko)
|
2013-11-05 |
2016-08-05 |
코그네이트 바이오서비시즈, 인코포레이티드 |
암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
|
|
CA2931322A1
(en)
|
2013-11-22 |
2015-05-28 |
Dnatrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
WO2015082376A2
(en)
|
2013-12-03 |
2015-06-11 |
Bayer Pharma Aktiengesellschaft |
Use of pi3k-inhibitors
|
|
GB201405834D0
(en)
|
2014-04-01 |
2014-05-14 |
Univ London Queen Mary |
Oncolytic virus
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
CA2954476C
(en)
|
2014-07-10 |
2023-09-19 |
Novartis Ag |
Immune-stimulating monoclonal antibodies against human interleukin-2
|
|
DK3169341T3
(da)
|
2014-07-16 |
2019-08-05 |
Transgene Sa |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
AU2015289081B2
(en)
|
2014-07-16 |
2020-02-06 |
Transgene Sa |
Combination of oncolytic virus with immune checkpoint modulators
|
|
RU2749113C2
(ru)
*
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
US20190038713A1
(en)
*
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
JP2019513021A
(ja)
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
AU2018287317B2
(en)
*
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|